Biotech Losers: Inovio Pharmaceuticals (NYSEMKT:INO), Oncomed Pharmaceuticals (NASDAQ:OMED), Enzymotec (NASDAQ:ENZY), Veracyte Inc (NASDAQ:VCYT)

Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) announced financial results for the quarter and year ended December 31, 2013. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. Traded volume was 10,401,414 million shares in the last session and the average volume of the stock remained 7.79 million shares. The beta of the stock remained 3.69. Inovio Pharmaceuticals Inc (NYSEMKT:INO) insider ownership is 0.30%.

Oncomed Pharmaceuticals (NASDAQ:OMED) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research note issued to investors on Tuesday, American Banking reports. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) dropped -6.68 percent to $31.03 yesterday on volume of 300,852.00 million shares. The intra-day range of the stock was $30.40 to $34.20. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has a market capitalization of $914.78 million.

Enzymotec Ltd. (Nasdaq:ENZY) (the “Company”) today announced the pricing of a registered secondary public offering. The size of the offering has been increased to 4,698,857 ordinary shares at a price of $28.00 per share. Enzymotec Ltd (NASDAQ:ENZY)’s stock on Mar 25, 2014 reported a decrease of -6.45% to the closing price of $22.92. Its fifty two weeks range is $14.25 -$35.12. The total market capitalization recorded $498.75 million. The overall volume in the last trading session was 302,333 million shares. In its share capital, Enzymotec Ltd (NASDAQ:ENZY) has 21.55 million outstanding shares.

Stock analysts at Cowen and Company increased their target price on shares of Veracyte (NASDAQ:VCYT) from $17.00 to $22.00 in a report issued on Wednesday, Analyst RN reports. The firm currently has an “outperform” rating on the stock. On Tuesday, shares of Veracyte Inc (NASDAQ:VCYT) dropped -6.44% to close the day at $16.41. Company return on investment (ROI) is 32.50% and its monthly performance is recorded as 11.18%. Veracyte Inc (NASDAQ:VCYT) quarterly revenue growth is 17.21%.